MetaCap

Cronos Group Inc. (CRON)

NASDAQ: CRONHealth Care Medicinal Chemicals and Botanical Products USD

3.04-0.04 (-1.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRON stock chart

Technical analysis

Key statistics

All statistics
52-week range
2.35 – 3.91
Day range
3.02 – 3.12
Volume / Avg
1.92M / 1.07M
Beta
—

52-week range

$2.35$3.91

CRON stock today

On Nov 20, CRON ended the session at $3.04, shedding $0.04 (1.30%), versus the S&P 500's 3.70% decline. At this level, CRON sits in the middle of its 52-week range of $2.35 to $3.91: 22.3% below the high, set on Nov 5, 2026 and 29.4% above the low. CRON is up 15.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.3%.

Cronos Group trades at 19.0x its trailing twelve-month earnings per share of $0.16.

Summary generated from market data by MetaCap's automated system. Methodology

About Cronos Group

Company profile

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Industry
Medicinal Chemicals and Botanical Products
CEO
Mr. Michael Ryan Gorenstein J.D.
Headquarters
Stayner, ON
Employees
610

Financial highlights

Full financials

In fiscal 2025, Cronos Group generated $146.6 million in revenue, up 24.6% from fiscal 2024, its 8th consecutive year of revenue growth. Cronos Group reported a net loss of $9.4 million, compared with net income of $41.1 million a year earlier. Gross margin was 42.8% (up from 21.4%) and operating margin -11.9%.

Cronos Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$146.59M$117.61M$87.24M$86.75M$64.56M
Growth+24.63%+34.82%+0.57%+34.37%+38.19%
Net income$-9.45M$41.08M$-73.96M$-168.73M$-396.11M
EPS (diluted)$-0.02$0.11$-0.19$-0.45$-1.07

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$2.93-3.62%

  • Strong buy 0
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.04 vs $0.03
Surprise
+33.33%

CRON news

All CRON news

Cronos Group peers

Health Care sector
CRON peer companies
CompanyPrice% ChgMarket capCompare
TRLVTrulieve Cannabis Corp. Subordinate Voting Shares8.68-7.17%$1.48Bvs CRON
OBIOOrchestra BioMed Holdings Inc.6.58-6.00%$517.88Mvs CRON
SNDLSNDL Inc.1.17-5.65%$285.20Mvs CRON
TLRYTilray Brands Inc.1.89-8.70%$279.32Mvs CRON
ACBAurora Cannabis Inc.4.16-2.35%$273.50Mvs CRON
USNAUSANA Health Sciences Inc.12.94-1.67%$239.24Mvs CRON
MDWDMediWound Ltd.13.59+0.37%$195.56Mvs CRON
CGCCanopy Growth Corporation0.427-9.97%$191.99Mvs CRON

Indexes, lists and sector

Cronos Group stock FAQ

What is Cronos Group's stock price today?

CRON last traded at $3.04 as of Nov 20, 4:00 PM EST, down 1.30% on the day. Prices are delayed at least 15 minutes.

What is CRON's P/E ratio?

CRON trades at a trailing P/E ratio of 19.00.

Who is Cronos Group's CEO?

Mr. Michael Ryan Gorenstein J.D. is the chief executive officer of Cronos Group Inc., which has about 610 employees.

What is the CRON 52-week high?

The 52-week high for CRON is $3.91 and the 52-week low is $2.35. The stock is currently 22.3% below its high.

Compare CRON